Temasek Holdings (Private) Ltd - Dec 3, 2021 Form 3 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role: 10%+ Owner
Signature: TLS Beta Pte. Ltd., By: /s/ Fidah Alsagoff, Authorised Signatory
Stock symbol: PEARQ
Transactions as of: Dec 3, 2021
Transactions value $: $0
Form type: 3
Date filed: 12/9/2021, 08:08 PM
Previous filing: Aug 30, 2021
Next filing: Feb 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
holding	PEARQ	Class A Common Stock						26.8M	Dec 3, 2021	See footnotes	F1, F2

Explanation of Responses:

Id	Content
F1	The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd.
F2	Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Content

The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd.

Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.